Single Dose, Open Label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters of BAY 94 9027 and Elocta
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Damoctocog alfa pegol (Primary) ; Efmoroctocog alfa
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Bayer
- 08 Dec 2020 Results of dose-normalized analyses presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 01 Sep 2019 Results assessing pharmacokinetic profiles of BAY94-9027 and rFVIIIFc published in the Annals of Hematology
- 13 Aug 2019 Primary endpoint (AUC from time 0 to the last data point (AUC0-tlast): non-inferiority of Jivi (BAY94-9027) with Eloctate (rFVIIIFc)) has been met, according to a Bayer media release.